Proactive Investors - Run By Investors For Investors

Alliance Pharma provides confident assessment of prospects

It also said it hoped to quickly resolve an issue raised by the Competition & Markets Authority
closeup of the desk of a doctors office with a bottle with pills in the foreground and a stethoscope in the background
The company owns and sells prescription drugs. It also has five star brands that are helping drive top-line growth

Alliance Pharma PLC (LON:APH) gave a confident assessment of prospects in an AGM statement and, separately, said it hoped to resolve objections raised by the watchdog over prescription drug pricing.

The AIM-listed firm was one of a number of companies cited in a document called a Statement of Objections issued by the Competition & Markets Authority (CMA). The mention related to the pricing of an anti-nausea treatment called prochlorperazine.

The company pointed out it hadn’t been involved in the distribution or pricing of prochlorperazine, which generated sales last year of £200,000, since it was licensed to Focus Pharmaceuticals in 2013.

“Alliance will review the Statement of Objections in detail and work closely with the CMA to resolve its alleged objections. Alliance strongly condemns anti-competitive practices,” the healthcare group said in a statement to shareholders.

Ahead of its annual meeting on Thursday, chairman David Cook said the group continued to perform well and in line with expectations, with continued growth coming from the business' international “star” brands.

Robust trading has seen the group generate “strong” free cash flow. So, in the absence of acquisitions, the debt-to-EBITDA ratio should fall below two-times during the second half, Cook confirmed.

View full APH profile View Profile

Alliance Pharma PLC Timeline

Newswire
January 21 2019

Related Articles

Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use